Market Place
Sourcing Support
GSK bolsters case for long-acting HIV PrEP drug Apretude
16 Oct 2024 //
FIERCE PHARMA
ViiV Healthcare To Triples Supply Of Long-Acting HIV PrEP
07 Oct 2024 //
BUSINESSWIRE
ViiV Healthcare To Present Dovato Vs Biktarvy Trial Data At AIDS 2024
15 Jul 2024 //
BUSINESSWIRE
UK MHRA grants Mkt approval for ViiV`s cabotegravir formulations prevent HIV-1
04 May 2024 //
PHARMABIZ
ViiV Healthcare Announces Data at CROI Indicating Efficacy of Cabenuva
06 Mar 2024 //
BUSINESSWIRE
GSK`s new HIV drug formula could support longer dosing intervals
05 Mar 2024 //
PRESS RELEASE
GSK`s injectable HIV drug shows promise over daily pills
22 Feb 2024 //
PRESS RELEASE
ViiV Healthcare receives approval from China’s NMPA for Vocabria
27 Oct 2023 //
PRESS RELEASE
European Commission authorises GSK`s HIV prevention drug
20 Sep 2023 //
REUTERS
MSF calls out GSK`s ViiV for nondisclosure clauses in contract
17 Aug 2023 //
FIERCE PHARMA
GSK`s HIV prevention drug recommended for marketing approval in Europe
25 Jul 2023 //
PRESS RELEASE
GSK`s ViiV explores novel pathway to expand long-acting HIV drug
06 Jul 2023 //
FIERCE PHARMA
GSK licenses companies to make cheap copies of HIV prevention drug
30 Mar 2023 //
REUTERS
GSK`s ViiV says its long-acting HIV shot as effective as Gilead`s daily pill
23 Feb 2023 //
REUTERS
FDA approves Gilead`s long-acting HIV injectable Sunlenca
23 Dec 2022 //
FIERCEPHARMA
EMA validates ViiV ’s MAA for cabotegravir long-acting inj for HIV prevention
29 Oct 2022 //
PHARMABIZ
GSK`s HIV franchise could reach £7B in 2026: analyst
22 Oct 2022 //
FIERCEPHARMA
GSK feeds HIV PrEP drug to patent pool amid US launch
29 Jul 2022 //
FIERCEPHARMA
FDA Approves CABENUVA; Expands Indication of Injectable HIV Regimen
29 Mar 2022 //
PRESS RELEASE
ViiV wins another label update for long-acting HIV injectable Cabenuva
25 Mar 2022 //
ENDPTS
ViiV Healthcare’s readiness for voluntary licensing for cabotegravir in HIV
14 Mar 2022 //
PHARMABIZ
GSK snags FDA nod for long-acting HIV PrEP injectable
22 Dec 2021 //
FIERCEPHARMA
FDA approves first injectable treatment for HIV pre-exposure prevention
21 Dec 2021 //
PHARMAFILE
US clears ViiV`s long-acting drug for HIV pre-exposure prevention
20 Dec 2021 //
HEALIO
FDA approves first injectable treatment for HIV pre-exposure prevention
20 Dec 2021 //
EXPRESSPHARMA
FDA approves injectable form of GSK HIV prevention drug
20 Dec 2021 //
REUTERS
ViiV Healthcare announces EC Decision for Vocabria, Rekambys injections for HIV
28 Oct 2021 //
BUSINESSWIRE
ViiV Healthcare presents positive interim data showing Vocabria
28 Oct 2021 //
PRESS RELEASE
Don’t wait for Shingrix rebound this year, says GSK
27 Oct 2021 //
FIERCEPHARMA
Positive SMC decision for first long-acting injectable HIV treatment
12 Oct 2021 //
PHARMAFIELD
Shionogi licenses out 3rd-gen HIV asset to ViiV
29 Sep 2021 //
FIERCEBIOTECH
GSK moves step closer to a nod for long-acting HIV PrEP therapy
28 Sep 2021 //
FIERCEPHARMA
Long-Acting Cabotegravir, Rilpivirine Inj. Effective Maintenance Therapy for HIV
20 Jul 2021 //
PRESS RELEASE
GSK`s ViiV preps doctors ahead of Cabenuva marketing push
24 May 2021 //
FIERCEPHARMA
ViiV Healthcare starts rolling submission of cabotegravir for HIV prevention
05 May 2021 //
PHARMACEUTICAL-TECHNOLOGY
Achilles` heel spotted for promising HIV prevention drug
10 Mar 2021 //
NATURE
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir)
21 Jan 2021 //
PRNEWSWIRE
FDA approves first extended-release injectable, complete regimen for HIV
21 Jan 2021 //
EUROPEANPHARMACEUTICALREVIEW
ViiV’s cabotegravir scores breakthrough designation for HIV prevention
18 Nov 2020 //
PHARMATIMES
GSK & ViiV score breakthrough therapy designation in HIV prevention
18 Nov 2020 //
ENDPTS
ViiV Healthcare announces investigational injectable cabotegravir
09 Nov 2020 //
BUSINESSWIRE
GSK says it is within weeks of resubmitting HIV injection Cabenuva
02 Jul 2020 //
REUTERS
New, long-acting PrEP injection found to effectively prevent HIV transmission
24 May 2020 //
IGBTQNATION
Long-Acting Injectable Cabotegravir Is Highly Effective for HIV Infection
18 May 2020 //
GLOBENEWSWIRE
ViiV sees first global approval of Cabenuva in Canada
23 Mar 2020 //
PHARMATIMES
GSK`s ViiV nabs first approval for HIV game-changer Cabenuva
21 Mar 2020 //
FIERCE PHARMA
Independent Pharmacy-Owned Indy Health Insurance To Launch Medicare-D Plan
09 Mar 2020 //
PR NEWSWIRE
Complete Response Letter Issued from U.S. FDA for Investigational HIV Regimen
20 Dec 2019 //
PR NEWSWIRE
Top GSK/ViiV scientist who co-invented an HIV blockbuster books to biotech
25 Sep 2019 //
ENDPTS
Eight weeks between each HIV treatment? GSK notches PhIII win as it chases OK
23 Aug 2019 //
ENDPTS
Janssen reports positive Ph3 results of long-acting injectable HIV treatment
23 Aug 2019 //
BIOSPECTRUMASIA
ViiV’s long-acting HIV regimen passes late-stage trial
22 Aug 2019 //
CLINICALTRIAL SARENA
Long-lasting HIV injection is a step closer after second GSK study
31 Oct 2018 //
REUTERS
Encouraging data for ViiV’s long-acting, two-drug HIV therapy
30 Oct 2018 //
PHARMA TIMES
GlaxoSmithKline scores new win for 2-drug HIV regimen long-acting version
15 Aug 2018 //
FIERCE PHARMA
ViiV starts trial of HIV-preventing injections for women
05 Dec 2017 //
PMLIVE
Fresh off its Juluca approval, GSK beefs up trials of long-acting HIV duo
28 Nov 2017 //
FIERCE PHARMA
ViiV’s long-acting two-drug HIV regimen hits targets
25 Jul 2017 //
PHARMA TIMES
